Genome-wide association studies (GWAS) have previously identified 13 loci associated with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL). To identify additional CLL susceptibility loci, we conducted the largest meta-analysis for CLL thus far, including four GWAS with a total of 3,100 individuals with CLL (cases) and 7,667 controls. In the meta-analysis, we identified ten independent associated SNPs in nine new loci at 10q23.31 (ACTA2 or FAS (ACTA2/FAS), P = 1.22 × 10 −14 ), 18q21.33 (BCL2, P = 7.76 × 10 −11 ), 11p15.5 (C11orf21, P = 2.15 × 10 −10 ), 4q25 (LEF1, P = 4.24 × 10 −10 ), 2q33.1 (CASP10 or CASP8 (CASP10/CASP8), P = 2.50 × 10 −9 ), 9p21.3 (CDKN2B-AS1, P = 1.27 × 10 −8 ), 18q21.32 (PMAIP1, P = 2.51 × 10 −8 ), 15q15.1 (BMF, P = 2.71 × 10 −10 ) and 2p22.2 (QPCT, P = 1.68 × 10 −8 ), as well as an independent signal at an established locus (2q13, ACOXL, P = 2.08 × 10 −18 ). We also found evidence for two additional promising loci below genome-wide significance at 8q22.3 (ODF1, P = 5.40 × 10 −8 ) and 5p15.33 (TERT, P = 1.92 × 10 −7 ). Although further studies are required, the proximity of several of these loci to genes involved in apoptosis suggests a plausible underlying biological mechanism.
a r t i c l e s CLL is a B-cell malignancy with a strong familial component 1 and an ~8.5-fold increased relative risk in first-degree relatives 2 . Previous CLL GWAS have identified 13 loci that explain a portion of the familial risk [3] [4] [5] [6] , suggesting that additional loci of modest effects can be found using a larger discovery sample size 7 .
RESULTS
As part of a larger initiative in non-Hodgkin's lymphoma (NHL) (called the NHL GWAS), we genotyped 2,343 cases and 2,854 controls of European descent from 22 studies using the Illumina OmniExpress Beadchip (Online Methods and Supplementary Table 1) . Of those 5,197 subjects, 94% passed rigorous quality-control criteria (Online  Methods and Supplementary Table 2) , and 549,934 SNPs successfully passed quality-control criteria with a median call rate >98%. We also used genotype data previously generated on the Illumina Omni2.5 from an additional 3,536 controls and 1 case from three studies 8 , giving a total of 2,179 cases and 6,221 controls for the analysis of the NHL GWAS data (Supplementary Table 3 ).
In the NHL GWAS (stage 1) analysis, we observed an enrichment of SNPs with small P values compared to the null distribution with a λ value of 1.026 in the quantile-quantile plot (Supplementary Fig. 1 ). After exclusion of previously established loci, an excess of small P values still remained, suggesting there are additional susceptibility loci. In our stage 1 analysis, we observed SNPs from ten unique loci (defined as separated by at least 500 kb and with linkage disequilibrium (LD) r 2 < 0.05) that reached genome-wide significance (P < 5 × 10 −8 ), including eight established loci and two new loci (Supplementary Fig. 2) .
We then performed a meta-analysis of the NHL GWAS data with three other independent CLL GWAS 5,9 that had a combined total of 921 cases and 1,446 controls (stage 2; Supplementary Tables 1 and 3). Because these other CLL GWAS studies were conducted on different commercial SNP microarrays, we imputed common SNPs from the 1000 Genomes Project 10 using IMPUTE2 (ref. 11) (Online Methods and Supplementary Table 4 ). In the meta-analysis of the data from stages 1 and 2, associations for all 13 established loci showed a consistent direction of effect with previously reported studies, and 10 loci achieved P < 5 × 10 −8 (Supplementary Table 5 ). However, two previously established loci, 15q25.2 and 19q13.3, were only nominally significant in the meta-analysis (P = 0.03 and P = 0.008, respectively), and we found no significant association in stage 1 for the 15q25.2 locus (P = 0.10). A suggestive locus on 18q21.1 that did not meet genome-wide significance in previous studies 12 was also nominally significant here (P = 5.06 × 10 −4 ). From the meta-analysis of stages 1 and 2, we identified ten promising SNPs in the eight new loci and one promising SNP in an established locus that we carried forward for a de novo replication in stage 3; this stage included an additional 392 cases and 4561 controls and in silico replication in an independent CLL GWAS with 396 cases and 311 controls (Online Methods and Supplementary Tables 1,3 and 4).
Significant new loci
Seven of the ten SNPs in new loci reached genome-wide significance in the meta-analysis of all three stages: 10q23.31 (ACTA2/FAS, P = 1.22 × 10 −14 ), 18q21.33 (BCL2, P = 2.66 × 10 −12 ), 11p15.5 (C11orf21, P = 2.15 × 10 −10 ), 4q25 (LEF1, P = 4.24 × 10 −10 ), 2q33.1 (CASP10/CASP8, P = 2.50 × 10 −9 ), 9p21.3 (CDKN2B-AS1, P = 1.27 × 10 −8 ) and 18q21.32 (PMAIP1, P = 2.51 × 10 −8 ) ( Table 1 and Fig. 1) . Further, within the 18q21.33 locus, a second SNP (rs4987852) in low LD (r 2 = 0.01) with rs4987855 and located only 372 bp away also reached genome-wide significance ( Table 1 ; P = 7.76 × 10 −11 ); we determined this SNP to be independent in conditional analyses (P conditional = 3.87 × 10 −7 ; Table 2 ).
a r t i c l e s
To explore these regions in greater detail and identify additional loci that we may have missed using just the genotyped SNPs in stage 1, we imputed the stage 1 data of our NHL GWAS using 1000 Genomes Project 10 data (February 2012 release) and performed a meta-analysis of the results from stages 1 and 2. The most significant SNPs at three of our new loci, 10q23.31 (rs2147420) 18q21.33 (rs4987856) and 4q25 (rs2003869), were highly correlated (r 2 ≥ 0.95) with our strongest genotyped SNPs, rs4406737, rs4987885 and rs898518, respectively (Supplementary Table 6 ). We found only modest correlations (r 2 range 0.18-0.58) for the most significant imputed SNPs at 11p15.5 (rs2521269), 2q33.1 (rs11688943) and 9p21.3 (rs1359742) with our strongest genotyped SNPs in each of the respective regions. The most significant of the imputed SNPs at 18q21.32 (rs35748167) seemed to be independent of our strongest genotyped SNP (rs4368253, r 2 = 0.003, P conditional < 7.89 × 10 −7 for both SNPs), suggesting a possible second, independent signal ( Table 2) .
Meta-analysis of our imputed scan data identified two new loci, 15q15.1 (BMF, P = 2.71 × 10 −10 ) and 2p22.2 (QPCT, P = 1.68 × 10 −8 ) ( Table 1 and Fig. 1 ). In addition, although our genotyped SNP at 5p15.33 (TERT, rs10069690, P = 1.92 × 10 −7 ) (Supplementary Table 7 ) Table 7 ). Additional studies are needed to confirm these findings, particularly the signal on 5p15.33, which is already known to harbor risk variants for multiple cancers [13] [14] [15] [16] [17] [18] [19] [20] . 
An examination of established loci revealed a new SNP in 2q13 (BCL2L11, rs13401811, P = 6.09 × 10 −17 ; Table 1 and Fig. 2 ) that was independent of the previously reported SNP. After conditioning on the established 2q13 SNP (rs17483466, r 2 = 0.02), the new SNP rs13401811 remained strongly associated with CLL risk (P conditional = 1.60 × 10 −12 ; Table 2 ). We found a putative second signal at the established 2q37.3 locus (Supplementary Table 5 ; rs7578199, P = 5.39 × 10 −7 ) that was in low LD with (r 2 = 0.01), and independent of, the previously reported SNP rs757978 (P conditional = 6.10 × 10 −6 ; Table 2), although rs7578199 was not genome-wide significant. We observed another possible second signal on 6p21.32 (Supplementary Table 5 ; HLA, rs9273363, P = 2.24 × 10 −10 ). rs9273363 showed some evidence Table 2 ). However, rs9273363 may be part of a shared HLA haplotype, and thus accurate HLA typing is needed to further clarify its level of independence. In addition, we observed a SNP at 15q21.3 (Supplementary Table 5 ; rs11636802, P = 1.68 × 10 −13 ) that had stronger statistical significance than the previously reported SNP, rs7169431 (P = 1.72 × 10 −05 ). Although only modestly correlated (r 2 = 0.16), rs11636802 explained all of the risk associated with rs7169431 in a conditional analysis ( Table 2) , suggesting that this SNP may be a better marker for the locus.
Explained variance
Heritability analysis indicated that the ten independent SNPs in our new loci together with the new independent SNP at 2q13 ( Table 1) explain approximately 5% more familial risk in addition to the ~12% explained by the established loci. When we explored the contribution of all common variants to the genetic heritability of CLL (using a method that estimates the variance explained by fitting all genotyped autosomal SNPs simultaneously 21, 22 ; Online Methods) 21, 22 , we estimated that common SNPs have the potential to explain up to ~46% of the familial risk, suggesting that more common loci, probably of small effects, still remain to be discovered. However, the analysis also implied that common SNPs probably do not explain all of the familial risk, and other factors, such as uncommon SNPs with modest effects or rare highly penetrant variants, probably also have a role.
Biological inferences
Five of the new loci (10q23.31, 18q21.33, 2q33.1, 18q21.32 and 15q15.1) identified in this study, as well as the new SNP at the established 2q13 locus, are located in or near genes involved in apoptosis. rs4406737 is located on 10q23.31 between the first and second exons of FAS, a member of the tumor necrosis factor receptor superfamily that has a crucial role in the initiation of the signaling cascade of the caspase family in apoptosis. Mutations in FAS leading to defective FAS-mediated apoptosis have been documented in inherited lymphoproliferative disorders associated with autoimmunity 23, 24 , and families with germline FAS mutations have a substantially increased risk of other lymphoma subtypes 25 .
The two newly identified SNPs at 18q21.33 (rs4987855 and rs4987852) map to the 3′ UTR of CBL2 (B-cell CLL/lymphoma 2), which encodes an essential outer mitochondrial membrane protein that blocks lymphocyte apoptosis. Constitutive expression of BCL2 through t(14;18) and other translocations is common in follicular lymphomas, but the t(14;18) translocation is also found in CLL, albeit rarely 26 . Both SNPs are located within a narrow region of BCL2 in which the majority of t(14;18) translocation breakpoints occur 27 . rs4987855 is in LD with a SNP (rs4987856, r 2 = 1.0) that is located within 200 bp of a putative microRNA binding site for miR-195 (ref. 28 ) and has been found to be nominally correlated with BCL2 expression (Supplementary Table 8 ; P = 0.02) 29 . Forced overexpression of BCL2 in mice leads to an increased incidence of B-cell lymphomas 30 .
The new SNPs at 18q21.32 and 15q15.1, as well as the new SNP at the established 2q13 locus, are located near BCL2 family member genes. rs4368253 is located approximately 51 kb downstream from PMAIP1 (phorbol-12-myristat-13-acetate-induced protein 1), which encodes the proapoptotic BCL2 protein NOXA. Regulation of apoptosis through NOXA is crucial for B-cell expansion after antigen triggering 31 . Downregulation of NOXA contributes to the persistence of CLL B cells in the lymph node environment 32 . rs8024033 is located approximately 5.4 kb upstream of BMF (BCL2 modifying factor), which encodes an apoptotic activator that binds 
to BCL2 proteins. BMF has been implicated in the survival of chronic lymphocytic leukemia cells 33 , and loss of Bmf in mice leads to B-cell hyperplasia and an accelerated development of radiation-induced thymic lymphomas 34 . The new SNP (rs13401811) at 2q13, a locus previously implicated in risk of CLL 3, 35, 36 and more generally in B-cell NHL 37 , is located approximately 262 kb upstream of BCL2L11 (BCL2-like 11). BCL2L11 encodes a proapoptotic member of the BCL2 family, BIM, which has a key role in the regulation of apoptosis in T-and B-cell homeostasis. Loss of Bim accelerates Mycinduced leukemia in mice 38 , and this SNP has been previously reported to be nominally associated with CLL in a small candidate gene study 39 .
The new 2q33.1 SNP (rs3769825) resides in intron 2 of CASP8 (caspase-8) and is in LD with a missense SNP (rs13006529, r 2 = 0.71) in the nearby gene CASP10 (caspase-10) (Supplementary Table 9 ), both of which have a central role in cell apoptosis. SNPs within this region have been associated with breast cancer 40 , esophageal cancer 41 and melanoma 42 susceptibility. SNPs in CASP8/CASP10, including one in moderate LD with the SNP we found here (rs11674246, r 2 = 0.66), were previously nominally associated with CLL risk in smaller casecontrol studies 43, 44 .
The remaining four new loci (11p15.5, 4q25, 9p21.3 and 2p22.2) map to other biologically interesting genes. The 4q25 SNP, rs898518, is located between the fourth and fifth exons of LEF1 (lymphoid enhancer-binding factor 1), which encodes a transcription factor involved in the WNT signaling pathway, an essential component in the normal homeostasis of hematopoietic stem cells 45 . Aberrant protein expression of LEF1 has been observed in CLL cells and monoclonal B-cell lymphocytosis, suggesting that LEF1 has an early role in CLL leukemogenesis 46 . rs1679013 maps to an intergenic region on 9p21.3 roughly 200 kb upstream from CDKN2B-AS1, an antisense noncoding RNA implicated in the risk of acute lymphocytic leukemia 47 . The 2p22.2 SNP (rs3770745) is located approximately 52 kb upstream of PRKD3 (protein kinase D3), which encodes a protein that interacts with transcriptional repressor, B-cell lymphoma 6 (BCL6). The 11p15.5 region contains many imprinted genes and has been implicated in Beckwith-Wiedemann syndrome 48 , a disorder characterized by excessive growth and a high incidence of childhood tumors 49 .
DISCUSSION
Our large GWAS of CLL identified ten associated SNPs in nine new loci and one new independently associated SNP in a previously reported locus. Together with the previously established loci, the cumulative set of SNPs correspond to an area under the curve of 0.73. Although further studies are required to fine map the regions, the proximity of several of these loci to genes involved in apoptosis suggests a possible underlying mechanism of biological relevance. Our results further support a substantial contribution of common gene variants in the pathogenesis of CLL.
METhODS
Methods and any associated references are available in the online version of the paper. Figure 2 Association results, recombination hotspots and LD plot for the new independent CLL susceptibility SNP in the established 2q13 locus. Top, association results of GWAS data from the stage 1 NHL GWAS (gray diamonds), the stage 2 combined data (blue diamond), the stage 3 combined data (purple diamond) and the combined data from stages 1-3 (red diamond) plotted against the −log 10 P values (left y axis). Overlaid are the likelihood ratio statistics (right y axis) estimating putative recombination hotspots across the region on the basis of five unique sets of 100 randomly selected control samples. Bottom, LD heat map based on r 2 values from the total control populations for all SNPs included in the GWAS. 
